Form 4: Puma Biotechnology Director Executes Stock Transactions

Director Troy E. Wilson acquired 27,000 restricted stock units and sold 10,800 shares of Puma Biotechnology common stock.

Summary

• Director Troy E. Wilson received a grant of 27,000 restricted stock units (RSUs) on June 11, 2026.
• The RSUs vest on the earlier of the one-year anniversary of the grant or the next annual shareholder meeting.
• On June 12, 2026, the director sold 10,800 shares of common stock at a weighted average price of $7.1989 per share.
• The sale was executed pursuant to a Rule 10b5-1(c) trading plan adopted on March 12, 2025.
• Following these transactions, the director holds 59,750 shares directly, plus 550 shares held indirectly by children.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction represents routine equity management by a director rather than a change in company fundamentals.

Positives

• The director maintains a significant direct ownership stake of 59,750 shares following the transactions.
• The sale was conducted under a pre-arranged 10b5-1 trading plan, which typically indicates a systematic approach to liquidity rather than reactive selling.

Negatives

• The director reduced their direct holdings by 10,800 shares through a market sale.

Risks

• Future vesting of the 27,000 RSUs is contingent upon the director's continued service with the company.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on director equity transactions.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for corporate executives and directors to manage personal liquidity while avoiding concerns regarding non-public information.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is consistent with best practices for corporate governance in the biotechnology sector to ensure transparency in insider transactions.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and represents a small portion of the director's total holdings.

Next Steps

• Vesting of the 27,000 restricted stock units on the earlier of the one-year anniversary or the next annual shareholder meeting.

Key Dates

Keywords

Puma Biotechnology, PBYI, Insider Trading, Form 4, Director, Equity Compensation